Antitumour Immunity Gets a Boost
Total Page:16
File Type:pdf, Size:1020Kb
RESEARCH NEWS & VIEWS mammals of the Mesozoic era (which spans the earliest known haramiyid fossil in fragmentation contributed to mammalian the Triassic, Jurassic and Cretaceous periods, Mammalia pulls mammalian origins back diversification during the Mesozoic. This is not from 252 million to 66 million years ago), it is in time to the Triassic period and before the the same as the diversification of the mamma- second in size only to the earlier, carnivorous break-up of the supercontinent Pangaea. This lian groups we see today; Mesozoic mammals Repenomamus giganticus from China2. But scenario favours a model of mammalian diver- unrelated to modern marsupials and placentals Vintana was a herbivore. Among its specializa- sification during the Jurassic and Cretaceous in swam like beavers, soared like flying squirrels tions are high-crowned molariform teeth with which the lineage leading to living marsupial and ate like foxes in the henhouse10. Living multiple islets of enamel, good for grinding and placental mammals was present for tens mammals are descended from only a small plant matter, and an expanded cheekbone to of millions of years before diversifying. The part of a strange and wonderful early radiation accommodate the attachment of large chewing alternative model, in which the first mammals of Mammalia, to which Vintana is a particu- muscles; the authors estimate that its bite force would have appeared in the Middle Jurassic, larly informative addition. ■ was twice that of a rodent of similar size. The about 175 million years ago, means that living animal also had relatively large eyes. This fact, lineages would have diversified more immedi Anne Weil is in the Department of Anatomy in combination with adaptations of the part of ately8. Last month, three new species of hara- and Cell Biology, Oklahoma State University the inner ear concerned with balance, suggests miyid were described, from near-complete Center for Health Sciences, Tulsa, Oklahoma that Vintana may have been agile and fast. specimens, with an analysis again favouring 74107, USA. Yet the skull also exhibits a few features the existence of Allotheria and its placement e-mail: [email protected] characteristic of earlier relatives that seem within Mammalia9. Now, using a third set of 1. Krause, D. W. et al. Nature 515, 512–517 (2014). to be the result of evolutionary reversals: the characters, a somewhat different sampling of 2. Hu, Y., Meng, J., Wang, Y. & Li, C. Nature 433, nose, palate and back of the skull contain bones taxa and all the new information vouchsafed 149–152 (2005). 3. Marsh, O. C. Am. J. Sci. 20, 235–239 (1880). generally thought to have been lost in the by Vintana, Krause and colleagues’ model also 4. Butler, P. M. Acta Palaeontol. Pol. 45, 317–342 (2000). mammalian lineage before the common supports the Allotheria grouping, the place- 5. Kielan-Jaworowska, Z., Cifelli, R. L. & Luo, Z.-X. ancestor of living mammals. And its long, ment of Vintana within Allotheria, and an Mammals from the Age of Dinosaurs: Origins, Evolution, and Structure (Columbia Univ. Press, 2004). down-turned snout would have given it a dis- ancient origin for Mammalia. 6. Zhou, C.-F., Wu, S., Martin, T. & Luo, Z.-X. Nature tinctive appearance. It may be that Vintana Analyses of fossil taxa with no living 500, 163–167 (2013). looks remarkable to us owing to its evolution descendants, of which Allotheria is an exam- 7. Zheng, X., Bi, S., Wang, X. & Meng, J. Nature 500, 199–202 (2013). during Madagascar’s long isolation, as Krause ple, produce varying results that are subject to 8. Cifelli, R. L. & Davis, B. M. Nature 500, 160–161 (2013). and colleagues propose, and indeed tooth the choice of animals included, the characteris- 9. Bi, S., Wang, Y., Guan, J. & Meng, J. Nature http:// wear suggests that it chewed differently from tics considered and the type of analysis used. If dx.doi.org/10.1038/nature13718 (2014). 10. Luo, Z.-X. Nature 450, 1011–1019 (2007). other gondwanatheres. But because we have the inclusion of Allotheria in Mammalia holds no comparable cranial material of other gond up, it may indeed prove to be that Pangaea’s This article was published online on 5 November 2014. wanatheres, it may also be that the entire group is similarly unusual. However outlandish Vintana may look, CANCER incorporating its skull into phylogenetic analyses at last provides an idea of where gond- wanatheres fit within Mammalia. It emerges that they share many characteristics with two Antitumour immunity groups of Mesozoic mammals now well known from the northern continents — multituber- culates and haramiyids — which together gets a boost comprise a group called Allotheria. Vintana is just the latest in an explosion of new discover- Five papers extend the list of cancers that respond to therapies that restore ies, and controversies, relating to this group. antitumour immunity by blocking the PD-1 pathway, and characterize those Originally conceived of to unite taxa within patients who respond best. See Letters p.558, p.563, p.568, p.572 & p.577 the mammalian lineage on the basis of teeth with rows of cusps3, Allotheria was eventually redefined to include the relatively common JEDD D. WOLCHOK & TIMOTHY A. CHAN termed ‘checkpoint blockade’ — referring multituberculate mammals and the then- to the use of antibodies that block immune- mysterious haramiyids, which were known he concept that the immune system inhibitory pathways switched on by cancer principally from isolated teeth4. has a role in controlling cancer is not cells. Five papers published in this issue5–9 Because the haramiyids were poorly a recent one. More than a century ago, reveal a growing list of cancers that respond known, the question of whether the grouping Tthe surgeon William Coley hypothesized to checkpoint blockade and describe charac- Allotheria reflects an evolutionary relation- that postoperative bacterial infections could teristics of those patients who respond to such ship has long been debated, so much so that mobilize a patient’s own resistance to tumour therapies. the foremost reference work on Mesozoic recurrence, and he developed a mixture of The immune checkpoints targeted by these mammals5 has one chapter entitled ‘Allotheri- heat-killed bacteria for intratumoral injec- therapies serve under normal conditions as ans’ and another denying that haramiyids were tion that occasionally produced durable molecular brakes, preventing hyperactivity of true mammals. Last year, two papers describ- regressions1. More recently, the elucidation of the T cells of the immune system and, in some ing the first haramiyid skulls and skeletons and molecular mechanisms underlying immune cases, preventing autoimmunity10. CTLA-4 including them in new phylogenetic analyses regulation has been instrumental in devising and PD-1 are two key cell-surface receptors arrived at competing hypotheses: one6 that strategies to overcome cancer cells’ ability to that, when bound by their ligands, trigger such haramiyids fell outside Mammalia, and the suppress the immune surveillance that would inhibitory pathways and dampen T-cell activ- other7 that they are closely related to Multi otherwise protect the host from tumour pro- ity. In the case of the PD-1 pathway, expression tuberculata and fell within Mammalia. gression2–4. One approach to activating these of ligands such as PD-L1 on tumour cells can This is not a trivial argument — including antitumour immune responses has been directly lead to the death of T cells expressing 496 | NATURE | VOL 515 | 27 NOVEMBER 2014 © 2014 Macmillan Publishers Limited. All rights reserved NEWS & VIEWS RESEARCH evident that the new antigens generated by a b Anti-PD-1 antibody such mutations are targeted by antitumour T cells, identifying which of these neo-antigens PD-L1 are functionally important has been a chal- Macrophage lenge. Yadav et al. sequenced the exomes (the protein-coding regions of the genome) of two mouse tumour-cell lines and compared these T cell with the reference mouse exome to predict Anti-PD-L1 antibody candidate neo-antigens in the tumour cells. In T-cell receptor parallel, they identified which of the neo-anti- PD-1 Neoantigen gens could potentially elicit immune responses PD-L1 by isolating those that bind to major histocom- MHC patibility complex (MHC) proteins, which pre- sent antigens to T cells, and then analysing the bound peptides by mass spectrometry. Tumour cell Surprisingly, this process identified only a few candidate neo-antigens, but these were highly immunogenic in vivo (that is, they pro- Inhibited antitumour immunity Enhanced antitumour immunity voked a strong immune response) and were found to be encoded by genes that are unlikely Figure 1 | Checkpoint blockade activates antitumour immunity. a, Tumour cells express both to directly contribute to cancer development, cancer-driving mutations and ‘passenger’ mutations that cause the expression of neoantigens — ‘new’ confirming that changes in immunogenicity molecular structures that, when presented by MHC proteins on the cell surface, are recognized by T cells can result from passenger mutations (Fig. 1). of the immune system as being foreign, leading to an immune response against the tumour. However, The approach presented in this report is a key interactions between the receptor PD-1 and its ligand PD-L1, which are expressed on tumour cells, T cells advance for the discovery of immunogenic and other immune cells such as macrophages, activate signalling pathways that inhibit T-cell activity and thus inhibit the antitumour immune response. b, Antibodies that block the PD-1 pathway by binding to antigens and is applicable to many experi- PD-1 or PD-L1 can reactivate T-cell activity and proliferation, leading to enhanced antitumour immunity. mental systems. However, it remains to be seen whether the low numbers of neo-antigens dis- covered reflects an inherently limited sensitiv- PD-1. Furthermore, engagement of CTLA-4 Ever since the earliest reports of the effects ity of the approach or whether the number of or PD-1, which are expressed both on T cells of PD-1 blockade14,15,17,18, PD-L1 expression by MHC-presented neo-antigens is indeed low.